| Schedule of Earnings (Loss) Per Share |
| | |
For the years ended March 31, | |
| | |
2025 | | |
2024 | | |
2023 | |
| | |
| | |
| | |
| |
| Earning (loss) per share – basic and diluted: | |
| | |
| | |
| |
| Numerator: | |
| | |
| | |
| |
| Net income (loss) attributable to the Company’s shareholders | |
$ | 5,587,625 | | |
$ | (1,373,504 | ) | |
$ | 1,986,119 | |
| Denominator: | |
| | | |
| | | |
| | |
| Weighted average number of ordinary shares outstanding | |
| 107,184,280 | | |
| 105,013,283 | | |
| 104,972,026 | |
| | |
| | | |
| | | |
| | |
| Earning (loss) per ordinary share – basic and diluted | |
$ | 0.05 | | |
$ | (0.01 | ) | |
$ | 0.02 | |
|
| Schedule of Ordinary Shares Equivalents Were Excluded from the Computation to Eliminate Any Antidilutive Effect |
The following ordinary shares equivalents were
excluded from the computation to eliminate any antidilutive effect:
| | |
As of | | |
As of | | |
As of | |
| | |
March 31,
2025 | | |
March 31,
2024 | | |
March 31,
2023 | |
| Warrant (1) | |
| 16,500,000 | | |
| - | | |
| - | |
| Ordinary shares placed in escrow (2) | |
| 4,328,394 | | |
| - | | |
| - | |
| (1) | For the years ended March 31, 2025, 2024, and 2023, the Company had the 16,500,000, 0, and 0 shares of
warrants, respectively, outstanding which were not included in the calculation of diluted net (income) loss per ordinary share because
inclusion thereof would be anti-dilutive |
| (2) | For the years ended March 31, 2025, 2024, and 2023, the Company had 4,328,394, 0, and 0 ordinary shares,
respectively, held in escrow. The Company has determined that these shares are non-participating securities in accordance with ASC 260,
as they are not entitled to dividends or other rights until certain milestones are met. As such, these shares are excluded from the calculation
of basic and diluted earnings (loss) per share for the respective periods. |
|